Y H Chang1, C L Tai2, H Y Hsu1, P H Hsieh1, M S Lee1, S W N Ueng1. 1. Chang Gung Memorial Hospital, Department of Orthopaedic Surgery, 5 Fu-Shin St., Kweishan, Taoyuan, 333, Taiwan. 2. Chang Gung University, Graduate Institute of Medical Mechatronics, Taoyuan, Taiwan.
This study aimed to find a simple, effective and ready-to-use
method to improve the efficiency of antibiotic release in antibiotic-loaded
bone cement (ALBC) for the treatment of clinical orthopaedic infection.We compared the elution characteristics, antimicrobial activity,
and mechanical properties of ALBC loaded with powder antibiotic,
powder antibiotic with inert filler (xylitol), or liquid antibiotic,
particularly focusing on vancomycin and amphotericin B.Adding vancomycin or amphotericin B antibiotic powder in distilled
water before mixing with bone cement can provide a significantly
higher efficiency of antibiotic release than that of bone cement
loaded with the same dose of antibiotic powder.This simple, inexpensive and effective method for the preparation
of ALBCs can significantly improve the efficiency of antibiotic
release in bone cement.Strengths: This is the first study to compare the efficiency
of antibiotic elution of ALBCs with different preparations.This study can provide a simple and ready-to-use method for orthopaedic
surgeons to prepare ALBC for treatment of infection in orthopaedics.Limitation: this is an in vitro study, which
does not necessarily reflect actual clinical circumstances.
Introduction
Antibiotic-loaded polymethylmethacrylate (PMMA) bone cements
have been widely used in the treatment of osteomyelitis. The ability
to deliver high local concentrations of antimicrobial agents has
made antibiotic-loaded PMMA one of the standards of treatment for
patients with chronic infection of the skeletal system, including
periprosthetic joint infection (PJI).[1]The efficiency of the release of antibiotics from bone cement
is a critical factor which determines the antibacterial activity
of antibiotic-loaded bone cement (ALBC). High porosity would be
expected to increase the release of antibiotics from ALBC. To increase
the porosity and thereby enhance the elution of antibiotics, various
inert fillers such as glycine and xylitol are added to bone cement.[2] These inert filler
materials, though effective for augmenting antibiotic release, are
not readily available in sterile form. Many powder antibiotics are
effectively released from bone cement.[3-5] In
contrast, liquid antibiotics have not been widely used in bone cement
because the mechanical integrity of the cement decreases by up to
50%.[6] Liquid
gentamicin in bone cement has been reported to elute effectively
and maintain its bactericidal activity,[7,8] and
liquid gentamicin combined with vancomycin in the same cement sample
demonstrated a positive reciprocal effect on the elution of both
antibiotics.[8] The
positive effect on the elution of antibiotics with the addition
of liquid gentamicin to bone cement is caused by the increased porosity
of the cement.[8] The
addition of a liquid antibiotic can therefore increase the porosity
of ALBCs, and it is reasonable to speculate that dissolution of
antibiotic powder in distilled water before mixing it with bone cement,
may provide more efficient antibiotic release than loading it with
the same dose of antibiotic powder.To our knowledge, no reports have compared the elution characteristics,
antimicrobial activity and mechanical properties of ALBCs loaded
with powder antibiotics, powder antibiotics with inert filler (xylitol),
or liquid antibiotics in an in vitro model. Vancomycin,
an antibiotic commonly loaded in ALBC, and amphotericin B, an antibiotic
expected to have a poor release profile in ALBC,[9] were used in this
experiment. We attempted to determine the difference in the profiles
of antibiotic release among ALBC with liquid antibiotic, powder
antibiotic, or powder antibiotic augmented with xylitol, particularly
focusing on vancomycin and amphotericin B, and the effect of liquid
antibiotics on the compressive strength of ALBC.
Materials and Methods
Antibiotic-loaded cement specimen
Surgical Simplex bone cement (Stryker Orthopaedics, Limerick,
Ireland) with powder (powder group), powder/xylitol (xylitol group)
or liquid (liquid group) vancomycin (Gentle Pharmaceutical Co.,
Yulin, Taiwan) or amphotericin B (China Chemical & Pharmaceutical
Co. Ltd, Taichung, Taiwan) was tested.In the powder group, the antibiotic–cement mixture consisted
of 2 g of antibiotic powder mixed with 40 g of bone cement polymer
prior to the addition of the monomer component. In the xylitol group,
the antibiotic–cement mixture consisted of 2 g of antibiotic powder
and 2 g of xylitol (Hiliga International Development Co. Ltd, Taipei,
Taiwan) mixed with 40 g of bone cement polymer prior to the addition
of the monomer component. In the liquid group, 2 g of antibiotic
powder was added in 12 ml of the distilled water and vortex for
30 seconds before mixing with bone cement. Subsequently, the antibiotic
liquid was added to 20 mL of monomer and mixed by hand with a metal
spatula before the powdered component was added.[8] The cement–antibiotic
mixture was also mixed by hand in a ceramic container for two minutes
until it achieved a doughy consistency, and was then manually pressed
into a plastic mold to form uniform cylindrical specimens. The cement
cylinders, 20 mm in height and 15 mm in diameter, were cured at
room temperature for one hour. A total of six antibiotic preparations
were added to bone cement: powder vancomycin, powder amphotericin
B, xylitol/powder vancomycin, xylitol/powder amphotericin B, liquid
vancomycin, or liquid amphotericin B. Bone cement without antibiotics
served as a control.
Antibiotic broth elution assay
Each cement cylinder was immersed in a polypropylene tube with
5 mL of phosphate-buffered saline (PBS, pH 7.3) and shaken in a
rotator at 37°C for 48 hours. The cement cylinders were then transferred
into a new test tube with PBS once they had been washed three times
a day in saline. The cumulative and daily antibiotic release was
measured, and 2 mL elution samples of PBS were collected at seven
time points over a period of ten days (Day 0, 1, 2, 3, 5, 7, and
10) and subsequently stored at -80°C until further analysis.The concentration of vancomycin was determined by using high-performance
liquid chromatography (HPLC). The method of HPLC analyses was modified
from previously published methods.[3,10] In
brief, the chromatography assay was performed using a model ALC
717 chromatograph (Waters Associates, Milford, Massachusetts) with
a stainless steel column (for vancomycin: RP18 column, 100 mm ×
4.6 mm, 5 µm particle size). The mobile phase was water/acetonitrile/100
mm ammonium formate (composite ratio: 78/12/10). The HPLC system
had a sensitivity of 0.5 µg/mL for vancomycin. The concentration
of vancomycin in the cement cylinders was obtained from the HPLC
analysis through comparisons made with the prepared daily standard
curves, where the peak areas were related with antibiotic concentrations.The concentration of amphotericin B was measured using visual
spectrum spectroscopy absorbance at 415 nm on a BMG Fluo Star Omega
(TECAN Infinite M200 PRO, Tocan Group Ltd, Switzerland). Standard
curves were generated from prepared samples with known concentrations
of amphotericin B. Amphotericin B was solubilised by mixing the
eluate samples 50:50 with dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
St Louis, Missouri) to disperse the micelles. The visual spectrum
spectroscopy system had a sensitivity of 0.1 μg/mL for amphotericin
B, the concentration of which was estimated by interpolation from
standard curves.
Bioassay of antibiotic activity
The bioactivity of joint fluid was estimated using an agar disk
diffusion bioassay with methicillin-resistant Staphylococcus
aureus (MRSA) (ATCC 43300) and Candida albicans (ATCC
90028) strains. The technique was based on the inhibitory activity
of disks (PDM Diagnostic Discs, AB Biodisk, Sweden) containing 35 µl
of test samples and standardised concentrations of vancomycin or
amphotericin B. The disks were placed on MRSA- or C. albicans-seeded
agar and incubated overnight at 37°C. The diameter of the inhibition
zones was measured using a caliper. All samples were tested three
times. The growth was visually compared with that of the control (without
the antibiotic) and standard samples with different concentrations
of antibiotics.
Ultimate compression test
The cement specimens (both before and after antibiotic broth
elution) in each group were tested for failure in axial compression
by using a material testing system (Bionix 858; MTS Corp, Eden Prairie,
Minnesota). A specially designed push rod with a self-alignment
function was used as a plunger to ensure full surface contact between
the specimen and the push rod. Each specimen was compressed at a
displacement rate of 0.1 mm/s. Force, displacement and time were
recorded simultaneously for each specimen in increments of 0.05 mm
by MTS Test Star software (MTS Corp.). The ultimate compressive
force was compared among groups. A cement specimen without antibiotics
was used as a control.
Statistical analysis
The antimicrobial concentration of elution samples and the ultimate
compressive force of cements with different preparations were tested
three times. The results were reported as the mean and standard
error of mean (sem). We used an ANOVA to determine the
statistical difference in the ultimate compression force and efficiency
of antibiotic release between cements with different preparation
methods. A p-value of < 0.05 was considered statistically significant.
Results
All tested samples showed burst release during the first day of
the broth elution assay, with the release rates rapidly decreasing
by the next time point (Fig. 1). The cement samples of the liquid
or xylitol group showed a significantly higher efficiency of antibiotic
release than that of the powder group in both the bone cement loaded
with vancomycin and that with amphotericin B (Fig. 1). During the ten-day
study period, vancomycin elution was enhanced by 234% in the liquid
group (total amount of vancomycin released: 1212 µg/ml; sem 59)
and by 12% in the xylitol group (total amount of vancomycin released:
406 µg/ml; sem 28) compared with the powder group (total
amount of vancomycin released: 362 µg/ml; sem 32; p <
0.05). Similar findings were observed for ABLCs loaded with amphotericin
B: Amphotericin B elution was enhanced by 265% in the liquid group
(total amount of amphotericin B released: 190 µg/ml; sem 19)
and by 65% in xylitol group (total amount of amphotericin B released:
86 µg/ml; sem 18) compared with the powder group (total
amount of amphotericin B released: 52 µg/ml; sem 10; p < 0.05). Regarding
the duration of release of the antibiotic in ALBCs, vancomycin-loaded
ALBCs released the antibiotic for up to ten days. Amphotericin B-loaded
ALBCs released the antibiotic for five days. The durations of antibiotic release
were not significantly different among groups, i.e., those consisting
of ALBC loaded with vancomycin or amphotericin B (p > 0.05).Graphs showing cumulative
antibiotic released from cement specimens loaded with different
preparations of a) vancomycin or b) amphotericin B in broth elution
assay for ten days. The data are presented as the cumulative release
of a) vancomycin or b) amphotericin B from cement specimens with
different preparations. Values are shown as the mean and standard
error of the mean for triplicate specimens in each group. *Significant
difference (p < 0.05) between powder and liquid groups. **Significant difference
(p < 0.05).Regarding the mechanical strength of the cement samples, the
mean compression modulus was significantly lower for specimens containing
liquid antibiotic than it was for control specimens and those containing
other preparations, both before and after the elution of the broth (p < 0.05;
Fig. 2). The ultimate compressive strength was reduced by 35% and
55% in specimens containing vancomycin liquid and amphotericin B
liquid, respectively, in comparison with the control. In contrast,
the ultimate compressive strength was increased by 5% in specimens
containing amphotericin B powder in comparison with the control
(Fig. 2). The compressive strength of ALBC did not significantly
decrease over ten days in elution, regardless of the use of ALBC
with different preparations (Fig. 2).Bar graph showing the mean ultimate
compressive strength of the cement samples before and after the
ten-day broth elution assay relative to cement without antibiotics
(control). Values are shown as the mean and standard error of the
mean for triplicate specimens for each group. *Significant difference
(p < 0.05) when compared with the control.With regard to the bioactivity of ALBC with different preparations
against test organisms, vancomycin and amphotericin B both retained
their antibacterial effects after incorporation into PMMA in powder,
xylitol/powder or liquid form. To test the bioactivity of vancomycin
or amphotericin B-loaded PMMA, MRSA and C. albicans, respectively,
were used. Based on the disk-diffusion assay of vancomycin, the
eluate samples of the liquid group exhibited a significantly larger
inhibitory zone than ALBC samples loaded with powder antibiotic
or powder antibiotic/xylitol (p < 0.05; Fig.3a). On the C.
albicans-seeded agar dish, only the eluate samples of the
liquid amphotericin B group exhibited a clear inhibitory zone (Fig.
3b). This inhibitory zone was not observed in the xylitol or powder
groups of amphotericin B-loaded PMMA.Charts showing antibacterial activity
of eluate samples from bone cement with different preparations,
as determined by agar-disk diffusion bioassay. The data are presented
in terms of inhibition of the test organisms: figure 1a - methicillin-resistant Staphylococcus
aureus and b) Candida albicans. The growth
was visually compared with standard samples containing different
concentrations of a) vancomycin and b) amphotericin B.
Discussion
Implant-related skeletal infection is one of the most devastating
complications of orthopaedic surgery. The most common pathogens
involved in skeletal infection are the Staphylococcus species,
which constitute 50% to 60% of all isolates.[11,12] Vancomycin,
a glycopeptide antibiotic, remains the standard therapeutic agent
used in most MRSA infections. Vancomycin has been shown to be stable in PMMA and is released
in a microbiologically-active form.[3] Vancomycin-loaded bone cement has
become one of the most common ALBC in the treatment of skeletal infection. In this study,
we found that ALBC loaded with liquid vancomycin presented a 3.3-fold
higher vancomycin release than ALBC loaded with powder vancomycin. This
simple, inexpensive, and effective method for the preparation of
ALBC can provide better release kinetics than traditional ALBC made
with antibiotic powder.Fungal skeletal infection is rare as it is estimated to occur
in approximately 1% of all cases of skeletal infection,[13,14] and remains a therapeutic challenge.[14] The efficacy of
antifungal-loaded bone cement spacers in the treatment of fungal
skeletal infection is controversial. Amphotericin B is a commonly
used antifungal agent. Placement of amphotericin B-loaded cement
spacers has been reported to successfully eradicate fungal skeletal infection.[15,16] However, amphotericin B has a highly hydrophobic
region that has been found to form covalent crosslinks in the PMMA
matrix.[9,17] Complete absence
of release of amphotericin B in an elution study using amphotericin
B-loaded bone cement has been reported.[9] Poor efficiency of antibiotic release
of amphotericin B-loaded ABLCs was also noted in this study. The accumulated
release of amphotericin B powder-loaded ALBC (52 µg/ml; sem 10)
was much worse than that of vancomycin power-loaded ALBC (362 µg/ml; sem 32)
in a ten-day broth elution assay. The eluate samples of amphotericin
B powder-loaded ALBCs did not exhibit a clear inhibitory zone in
the disk diffusion assay. These findings suggest that amphotericin
B powder-loaded ALBCs may not provide sufficient fungal eradication.
In our previous report, 50% of patients treated with two-stage exchange
arthroplasty for fungal PJI had recurrence or lack of control of
the infection.[14] Poor
antibiotic elution from the bone cement may explain why patients with
amphotericin B-impregnated cement spacers did not have a better
outcome than those without such spacers in our previous report.[14] In this study,
adding 2 g of amphotericin B in 12 ml of distilled water before
mixture with PMMA powder increased amphotericin B release by a factor
of 3.6, relative to loading with only 2 g of amphotericin B powder.
The eluate samples of ALBC with liquid amphotericin B exhibited
a clear inhibitory zone on the C. albicans-seeded
agar dish, which was not observed in ALBC with powder amphotericin
B augmented with or without xylitol. Therefore, liquid amphotericin
B ALBC may be a more effective measure in the treatment of fungal
infection.The kinetics of antibiotic release in ALBC depends on the penetration of dissolution
fluids into the polymer matrix and subsequent diffusion of the dissolved
drug from the ALBC. To increase antibiotic release, soluble fillers
such as glycine, xylitol, sucrose, or erythritol can be added into
the bone cement to increase its porosity and consequently increase
the penetration of dissolution fluids.[2,18,19] Xylitol has been
reported to be more effective than other soluble fillers in increasing
the amount of antibiotic release.[2] In
this study, addition of xylitol can improve the efficiency of ALBC
loaded with vancomycin or amphotericin B. However, even with the
addition of xylitol, the eluate samples from the amphotericin B-loaded
bone cement still did not exhibit a clear inhibitory zone in the
disk-diffusion assay. This finding indicates that even with the
addition of xylitol, amphotericin B-loaded ALBC is still unable
to provide a sufficient anti-fungal capacity. An additional drawback
of using xylitol as a filler is the lack of availability of aseptic xylitol,
thus resulting in a lack of readiness for its use in clinical applications.
In contrast, dissolution of the antibiotic powder in distilled water
before mixing with bone cement can significantly improve the efficiency
of antibiotic release (p < 0.05), even for amphotericin B-loaded
ALBC, which has been recognised as an ALBC with poor drug release.Liquid antibiotics in acrylic bone cement have been shown to
significantly compromise the mechanical properties of the cement
(p < 0.05).[7,20] International
industrial standards state that bone cement used for definitive
fixation must have an ultimate compressive strength of at least 70
MPa. This standard was established to reduce the incidence of premature
cement breakdown.[21,22] In this study, we
found that the ultimate compressive strength of cement specimens
was significantly compromised by loading with liquid antibiotics
(p < 0.05). The ultimate compressive strength of liquid antibiotic-loaded
ALBC was below 70 MPa both before and after broth elution. Therefore,
liquid-antibiotic-loaded ABLCs do not provide sufficient mechanical
strength for use in prosthesis fixation in total joint replacement.
However, it should be noted that the compressive strength of PMMA
is many times higher than that required in a clinical setting, and
that even a 35% to 55% decrease should not compromise its function
as a spacer. Additionally, ALBC beads are used as a therapeutic measure
and are temporary because they are typically exchanged or removed
from three to 14 days.Our study has some limitations. First, this is an in
vitro study of specimens prepared in a laboratory environment,
which does not necessarily reflect actual clinical circumstances.
The in vivo quantity and flow of body fluids, limb
mobility, host response, and antibiotic stability were not taken
into consideration. Second, only one type of bone cement and one
dose of antibiotic were used. Third, ATCC bacteria were selected
as test organisms in the experiment. The bioactivity of the cement specimens
against other bacteria, especially clinical isolates, remains unclear.To summarise, dissolution of 2 g of vancomycin or amphotericin
B antibiotic powder in 12 ml of distilled water before mixing with
bone cement can provide significantly higher efficiency of release
than that of bone cement loaded with the same dose of antibiotic
powder. However, inferior mechanical properties limit the use of the
liquid–antibiotic-loaded cement to temporary beads or spacers used
in the treatment of active infection and preclude it from being
used for the implantation of a prosthesis. This simple, inexpensive,
and effective method for preparation of ALBCs can significantly improve
the efficiency of bone cement in releasing antibiotics. Further
clinical studies are needed to determine the anti-infection efficiency
and safety of ALBCs prepared using this protocol.
Authors: Pedro Hinarejos; Pau Guirro; Lluis Puig-Verdie; Raul Torres-Claramunt; Joan Leal-Blanquet; Juan Sanchez-Soler; Joan Carles Monllau Journal: World J Orthop Date: 2015-12-18